Roche buys Telavant for $7.1 billion, gains access to novel IBD drug
Roche, a Swiss pharmaceutical giant, has agreed to a US$7.1 billion deal to acquire Telavant, a biotech company that is developing a promising drug for inflammatory bowel disease (IBD). Telavant is jointly owned by Roivant and Pfizer, two of Roche’s…